4D Molecular Therapeutics Inc (FDMT)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $689.52M
Last updated: Nov 17, 2026 at 4:33 PM ET
4D Molecular Therapeutics Inc (FDMT) Statistics
4D Molecular Therapeutics (FDMT) has a market cap of $689.52M and an enterprise value of $683.52M. Revenue grew 90637.74% over the last 12 months from the 12 months before. It kept -208.31% of revenue as net income over the last 12 months.
Total Valuation
Enterprise value is 0.87% below the market cap, as cash exceeds debt.
| Market Cap | $689.52M |
|---|---|
| Enterprise Value | $683.52M |
| Latest price (Nov 17, 2026) | $10.79 |
Key Dates
The next earnings report is expected on Mar 16, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 16, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 12, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 8.1x and 2.3x. Its year-end P/S ranged from 5.1x to 229.7x from 2020 to 2025.
| P/S Ratio | 8.1x |
|---|---|
| Forward P/S | 50.8x |
| P/B Ratio | 2.3x |
Price Statistics
The stock trades 16.94% below its 50-day average.
| Beta (1Y) | 1.96 |
|---|---|
| 1-Month Change | -12.21% |
| 3-Month Change | -35.62% |
| 6-Month Change | +28.38% |
| 5-Year Change | -50.48% |
| Total Return (1Y) | 0.00% |
| Total Return (3Y CAGR) | -3.98% |
| Total Return (5Y CAGR) | -14.01% |
| Return vs SPY (1Y) | -4.62% |
| Max Drawdown (1Y) | -38.34% |
| Max Drawdown (3Y) | -93.00% |
| Sharpe Ratio (1Y) | 0.09 |
| Correlation with SPY (1Y) | 0.35 |
| 50-Day Average | $12.99 |
| 200-Day Average | $11.10 |
| 52-Week Range | $6.96 to $16.93 |
| RSI (14 Days) | 39.8 |
| Average Volume (20 Days) | 1.02M |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 6.15x current liabilities, and total debt is 0.10x shareholder equity.
| Current Ratio | 6.15x |
|---|---|
| Quick Ratio | 6.15x |
| Debt / Equity | 0.10x |
Returns and Efficiency
Return on invested capital is -46.44% over the last 12 months, against a 5-year average of -24.18%.
| Return on Equity (ROE) | -59.29% |
|---|---|
| Return on Assets (ROA) | -46.73% |
| Return on Invested Capital (ROIC) | -46.44% |
| ROE (5Y Average) | -32.16% |
| ROA (5Y Average) | -28.87% |
| ROIC (5Y Average) | -24.18% |
| Asset Turnover | 0.23x |
Scores
FDMT has an Altman Z-Score of 1.40, in the distress zone below 1.81, and a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 1.40 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 2 of 9 |
| Piotroski Strength | Weak |
Income Statement
Revenue was $96.18M over the last 12 months.
| Revenue | $96.18M |
|---|---|
| Revenue Growth (YoY) | +90637.74% |
| Gross Profit | $96.18M |
| Operating Income | -$217.15M |
| Pretax Income | -$200.35M |
| Net Income | -$200.35M |
| Reported EPS (TTM) | -$2.70 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 78.82% of the $428.75M in total assets.
| Cash and Equivalents | $39.10M |
|---|---|
| Total Debt | $33.10M |
| Net Cash | $6.00M |
| Net Cash Per Share | $0.08 |
| Working Capital | $269.89M |
| Shareholder Equity | $337.94M |
| Book Value Per Share | $4.68 |
| Total Assets | $428.75M |
| Total Liabilities | $90.81M |
Balance sheet as of Sep 30, 2026.
Cash Flow
| Operating Cash Flow | -$166.28M |
|---|---|
| FCF Per Share | -$3.01 |
| Depreciation and Amortization | $6.22M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -225.77%.
| Gross Margin | 100.00% |
|---|---|
| Operating Margin | -225.77% |
| Pretax Margin | -208.31% |
| Net Margin | -208.31% |
Growth
Revenue grew 200.86% a year over 3 years.
| Revenue Growth (3Y CAGR) | +200.86% |
|---|---|
| Revenue Growth (5Y CAGR) | +44.32% |
| Book Value Per Share Growth (2Y CAGR) | +5.34% |
| Tangible Book Per Share Growth (2Y CAGR) | +5.34% |
Dividends and Yields
FDMT does not pay a dividend.
| Buyback Yield | -18.45% |
|---|---|
| Shareholder Yield | -18.45% |
Peer Position
Against 4 similar companies, FDMT has the 3rd highest P/S.
P/S RatioPeer median 8.1x
ROICPeer median -38.11%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median -100.00%
| P/S Ratio | 8.1x vs 8.1x median |
|---|---|
| ROIC | -46.44% vs -38.11% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +90637.74% vs -100.00% median |
Analyst Forecast
Consensus estimates put revenue growth at -55.62% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | -55.62% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Fairly valued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About FDMT
What is FDMT's market cap?
4D Molecular Therapeutics has a market cap of $689.52M. Its enterprise value, which adds debt and subtracts cash, is $683.52M.
How many shares of FDMT are outstanding?
4D Molecular Therapeutics has 72.25M shares outstanding. The count is up 28.73% from a year earlier.
Does FDMT pay a dividend?
No. 4D Molecular Therapeutics does not pay a dividend.
How much debt does FDMT have?
4D Molecular Therapeutics has $33.10M of total debt and $39.10M of cash and equivalents, a net cash position of $6.00M.
FDMT pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors